Answers are grounded in this paper and cite their sources.
Parkinson's disease (PD) is characterized by dopaminergic neuronal loss and α-synuclein aggregation, while current therapies remain symptomatic and limited. Low-intensity focused ultrasound (LIFU) has emerged as a non-invasive neuromodulation modality enabling precise targeting of deep brain structures. This review summarizes its applications in PD from mechanistic and translational perspectives. LIFU acts via two major pathways: direct modulation of cortico-basal ganglia circuits and blood-brain barrier opening for targeted drug delivery. It regulates key pathological processes, including α-synuclein aggregation, neuroinflammation and neurotrophic signaling. Despite promising pre-clinical and early clinical results, challenges remain in parameter optimization, variability and long-term safety, warranting further investigation for clinical translation.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: